Genentech's Lucentis restores diabetic vision loss, FDA says

Genentech Inc.'s eye drug Lucentis improved the vision of people with a type of blindness associated with diabetes, drug regulators said in a report Tuesday, according to the news agency Bloomberg. The report came in advance of a Food and Drug Administration advisory committee meeting Thursday in which Genentech hopes to expand the use of Lucentis from wet age-related macular degeneration to patients with diabetic macular edema.